Navigation Links
Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
Date:8/20/2007

SAN DIEGO, Aug. 20 /PRNewswire-FirstCall/ -- Lpath, Inc. (OTC Bulletin Board: LPTN), the category leader in therapeutic agents against bioactive lipids, reported that a standard panel of safety tests was recently completed with the humanized version of Sphingomab(TM), and the findings indicate no safety concern for systemic dosing of the antibody to humans.

Sphingomab, generated by Lpath's proprietary ImmuneY2(TM) platform technology, is a monoclonal antibody against the bioactive lipid S1P (sphingosine-1-phosphate). S1P has been well validated as a stimulator of angiogenesis (new blood-vessel growth), a process that has been strongly implicated in the pathology of both cancer and AMD.

The safety tests included cardiovascular studies in Cynomolgus monkeys as well as tests to evaluate the potential of the antibody to elicit the release of cytokines or an Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) reaction. The cardiovascular study included evaluation of the effect of humanized Sphingomab treatment on blood pressure, heart rate, and respiratory rate. The cardiovascular, cytokine release, and ADCC tests with humanized Sphingomab were all negative at doses or concentrations well above those expected to be needed in man to provide an anti-angiogenic action.

The panel of tests also included a pivotal multiple-dosing 28-day study in Cynomolgus monkeys. This study featured intravenous administration of humanized Sphingomab at doses as great as 100 mg/kg every three days for 28 days (10 total doses). Parameters monitored during this study included mortality, body weight, organ weight, clinical observations, ophthalmology, clinical pathology (hematology, clinical chemistry, coagulation, and urinalysis), and immune-phenotyping, both pre-treatment and on day 28 in all animals, and after one, two, three, and four weeks of recovery in a large sub- group of the animals.

No animal deaths occurred during the study. There were also no signific
'/>"/>

SOURCE Lpath, Inc.

Copyright©2007 PR Newswire.

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Lpath Demonstrates First-in-Class AMD Results With Its Lead Drug Candidate, Sphingomab
2. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
3. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
4. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
7. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
8. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
9. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
10. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
11. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013  Lakeland Industries, Inc. ... of protective clothing for industry, healthcare and to first ... release its financial results for the fiscal 2013 fourth ... May 21, 2013 at stock market close and will ... 4:30 p.m. eastern. (Logo: http://photos.prnewswire.com/prnh/20120611/NY21959LOGO ...
(Date:5/17/2013)... 17, 2013  Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... at the UBS Global Healthcare Conference in New ... 22 nd at 11 a.m. Eastern Time. To listen ... please visit the Investor Relations section of the Company,s Web ... for 14 days after the event. About Orexigen® ...
(Date:5/17/2013)... DIEGO and CAMBRIDGE, Mass., May 17, 2013 /PRNewswire/ ... that a purchaser of Aveo Pharmaceutical, Inc. (NASDAQGS: AVEO) ... Court for the District of Massachusetts ... its officers violated the Securities Exchange Act of 1934 ... 1, 2013 (the "Class Period"). (Logo: ...
Breaking Medicine Technology:Lakeland Industries to Report Fiscal Fourth Quarter and Year End Financial Results and Conduct Conference Call 2Aveo Pharmaceuticals, Inc. Sued by Investor 2Aveo Pharmaceuticals, Inc. Sued by Investor 3
(Date:5/18/2013)... (May 19, 2013) Each year, the American ... outstanding contributions and achievements in gastroenterology through its ... many distinguished and talented individuals who work tirelessly ... Today, we are pleased to announce the 2013 ... their colleagues for their tremendous contributions to our ...
(Date:5/18/2013)... 2013 Illuminations is proud to present the ... Seminars will take place over the course of four days, ... and Saturday, June 8, 2013. , Inner Child Therapy is ... on the attitudes, patterns and coping mechanisms that create the ... learn to live a more integrated and balanced life style, ...
(Date:5/18/2013)... MOOSGO.COM published an original art book for iPad ... group of artists who share their creations based on the ... Exclusively for iPad . , This work gathers ... that reflect the signature idiosyncrasy and passion of tango. Such ... Store and it includes a free trailer of the ...
(Date:5/18/2013)... In a May 14, 2013 article ... After Discovering Cancer Gene,” Fox News reported the movie ... that she carried a gene that doctors estimated gave ... a 50 percent risk of ovarian cancer (go to: ... 16, 2013 with a blog post entitled “A Patient’s ...
(Date:5/18/2013)... Transvaginal mesh lawsuits involving ... forward in a consolidated litigation underway in New Jersey’s ... to a notice on the Court’s website, the next ... will be held on Wednesday, May 22nd. Court ... the proceeding on behalf of women who suffered serious ...
Breaking Medicine News(10 mins):Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 2Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 3Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 4Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 5Health News:Illuminations Brings World Renowned Therapist to the Middle East 2Health News:New Art Book for iPad: Tango Art 2Health News:Angelina Jolie – Scarless Breast Augmentation Surgery 2Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 2Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 3
... , MONDAY, Nov. 2 (HealthDay News) -- Though someone ... lack basic knowledge about the potentially life-threatening disease, according ... , Diabetes is responsible for more deaths each year ... combined, but just 42 percent of those surveyed knew ...
... SINGAPORE, Nov. 2 /PRNewswire-Asia/ -- GfK Asia releases ... line with the,17th Hong Kong Optical Fair, hosted by Hong ... 2009 include China, Hong Kong, Korea,Singapore and Malaysia. The survey ... or the same in 2010. , ...
... cocoa, snuggling under blankets and heart attacks all have in ... months. , According to the Centers for Disease Control ... heart attack or similar cardiac event during or after a ... create awareness, work to lower that number, and highlight other ...
... professional athletes, who wear helmets in their careers, to help ... NEW YORK, Nov. 2 November is Epilepsy Awareness Month. ... American Epilepsy Outreach Foundation (AEOF) has joined with ... 1st Annual Helmets for Hope(TM) Campaign. The Helmets for Hope(TM) ...
... 2 In a dramatic settlement seen as a novel ... professional association, and one of the country,s biggest hospital systems ... on containing the spread of pandemics such as H1N1 "swine ... new course for limiting the spread of not only swine ...
... Preliminary evaluation after completion of treatment phase shows that, ... for patients with advanced-stage, platinum-resistant, taxane-pretreated ... AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS ) ... therapy and oncology, today announced positive efficacy data from ...
Cached Medicine News:Health News:Americans Get Failing Grade on Diabetes Awareness 2Health News:Americans Get Failing Grade on Diabetes Awareness 3Health News:Asian Optical Retailers Upbeat about 2010 2Health News:Asian Optical Retailers Upbeat about 2010 3Health News:MTD Joins Forces with the AHA to Promote Heart Health 2Health News:Helmets for Hope Campaign and Gala 2Health News:Dramatic Settlement Sets National Model for H1N1 Hospital Safety Measures 2Health News:Dramatic Settlement Sets National Model for H1N1 Hospital Safety Measures 3Health News:AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer 2Health News:AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer 3Health News:AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer 4
... Full Transportability: Innovative design allows the ... in for therapy or when to ... Choose the prophylactic method to deliver ... both simultaneously. ,Automatic Garment Detection: Automatically ...
Classic black cast boot with unisex styling...
... cast boot specially lasted for fiberglass ... rocker sole for easy ambulation! ,The ... narrow last so it fits better ... and with our stretchable upper, a ...
The Multi-Purpose Medical-Surgical Shoe...
Medicine Products: